Business
COSENTYX Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
COSENTYX offers growth opportunities due to a large patient base fueling recurring revenue, robust global demand, double-digit growth, and an expanding label across multiple inflammatory conditions. Innovations and lifecycle management, like a direct-to-patient platform, aim to maintain its competitive advantage.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "COSENTYX Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides insights i
About this update from Nov Inc.
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"COSENTYX offers growth opportunities due to a large patient base fueling recurring revenue, robust global demand, double-digit growth, and an expanding label across multiple inflammatory conditions. Innovations and lifecycle management, like a direct-to-patient platform, aim to maintain its competitive advantage.","length":314,"tagName":"p"},{"type":"text","content":"Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "COSENTYX Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.","length":170,"tagName":"p"},{"type":"text","content":"The report provides insights into COSENTYX's performance across major markets like the US, EU4, and Japan. It outlines approved indications and potential ones such as Graves ophthalmopathy and Discoid lupus erythematosus. The report covers COSENTYX's market dynamics, clinical efficacy, sales forecasts, and SWOT analysis. It explores competitive intelligence and provides strategies for commercial success in different geographies.","length":440,"tagName":"p"},{"type":"text","content":"COSENTYX Drug Summary","length":21,"tagName":"p"},{"type":"text","content":"COSENTYX, a fully human monoclonal antibody developed by Novartis, is approved for the treatment of several autoimmune inflammatory disorders. It targets interleukin-17A (IL-17A), reducing immune overactivity. Administered subcutaneously using various devices, COSENTYX demonstrates a strong safety profile but is contraindicated in cases of active tuberculosis.","length":362,"tagName":"p"},{"type":"text","content":"The market report presents insights into COSENTYX's strengt...